MIF was first characterized during studies on delayed-type hypersensitivity reactions, where it was found to inhibit macrophage migration . This discovery highlighted its potential role in immune regulation. Subsequent research revealed that MIF is stored in and secreted from the pituitary gland upon endotoxaemia, acting as a key regulator of innate immunity by counter-regulating glucocorticoids .
MIF is a pleiotropic cytokine with chemokine-like functions. It is involved in a wide range of cellular processes, including:
The production of recombinant MIF has enabled more detailed studies of its functions. Recombinant MIF is typically expressed in insect cells and purified for research purposes . This recombinant form retains the biological activity of the native protein and is used in various experimental settings to study its role in disease models.
Given its involvement in numerous pathological conditions, MIF is considered a potential therapeutic target. Inhibition of MIF signaling has shown promise in restoring anticancer immune responses in tumor microenvironments . Additionally, therapeutic interventions targeting MIF are being explored for their potential to modulate inflammation and tissue repair .